Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 2/20 | 0.52 |
| ▸ | CCNH | P51946 | 2/20 | 0.52 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195695 | 0.87 | CDK2 (0.52) | CDK2CDK1KCNH2 | |
| SCHEMBL3225072 | 0.81 | KCNH2 (0.53) | CDK2CDK7CDK9CCNKCDK12 | |
| SCHEMBL3225078 | 0.81 | KCNH2 (0.53) | CDK2CDK7CDK9CCNKCDK12 | |
| SCHEMBL4517750 | 0.79 | CDK2 (0.74) | CDK2CDK1KCNH2 | |
| SCHEMBL3210701 | 0.79 | KCNH2 (0.52) | CDK2CDK7CDK9CCNKCDK12 | |
| SCHEMBL3217699 | 0.79 | CDK2 (0.56) | CDK2CDK1KCNH2 | |
| SCHEMBL3210714 | 0.79 | KCNH2 (0.52) | CDK2CDK7CDK9CCNKCDK12 | |
| SCHEMBL4196604 | 0.79 | CDK2 (0.53) | CDK2CCNT1CCNE1CDK7CDK9 | |
| SCHEMBL3217705 | 0.79 | CDK2 (0.56) | CDK2CDK1KCNH2 | |
| SCHEMBL4193323 | 0.79 | CDK2 (0.53) | CDK2CCNT1CCNE1CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | CDK2 3/4885CCNT1 11/4885CCNE1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.